Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women

Denosumab, a human monoclonal antibody, acts against the receptor activator of nuclear factor-κB ligand and is a promising antiresorptive agent in patients with osteoporosis. This study aimed to update the efficacy and safety of denosumab vs. placebo in osteoporosis or low bone mineral density (BMD)...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yi, Zhu, Jun, Zhou, Yiqin, Peng, Jinhui, Wang, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080120/
https://www.ncbi.nlm.nih.gov/pubmed/33935694
http://dx.doi.org/10.3389/fphar.2021.588095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080120/
https://www.ncbi.nlm.nih.gov/pubmed/33935694
http://dx.doi.org/10.3389/fphar.2021.588095

Ejemplares similares